Using Exome Data to Identify Malignant Hyperthermia Susceptibility Mutations
Gonsalves, Stephen G. M.S.N.*; Ng, David M.D.†; Johnston, Jennifer J. Ph.D.‡; Teer, Jamie K. Ph.D.§; NISC Comparative Sequencing Program; Stenson, Peter D. Ph.D.#; Cooper, David N. Ph.D.**; Mullikin, James C. Ph.D.††; Biesecker, Leslie G. M.D.‡‡
Background: Malignant hyperthermia susceptibility (MHS) is a life-threatening, inherited disorder of muscle calcium metabolism, triggered by anesthetics and depolarizing muscle relaxants. An unselected cohort was screened for MHS mutations using exome sequencing. The aim of this study was to pilot a strategy for the RYR1 and CACNA1S genes.
Methods: Exome sequencing was performed on 870 volunteers not ascertained for MHS. Variants in RYR1 and CACNA1S were annotated using an algorithm that filtered results based on mutation type, frequency, and information in mutation databases. Variants were scored on a six-point pathogenicity scale. Medical histories and pedigrees were reviewed for malignant hyperthermia and related disorders.
Results: The authors identified 70 RYR1 and 53 CACNA1S variants among 870 exomes. Sixty-three RYR1 and 41 CACNA1S variants passed the quality and frequency metrics but the authors excluded synonymous variants. In RYR1, the authors identified 65 missense mutations, one nonsense, two that affected splicing, and one non–frameshift indel. In CACNA1S, 48 missense, one frameshift deletion, one splicing, and one non–frameshift indel were identified. RYR1 variants predicted to be pathogenic for MHS were found in three participants without medical or family histories of MHS. Numerous variants, previously described as pathogenic in mutation databases, were reclassified by the authors as being of unknown pathogenicity.
Conclusions: Exome sequencing can identify asymptomatic patients at risk for MHS, although the interpretation of exome variants can be challenging. The use of exome sequencing in unselected cohorts is an important tool to understand the prevalence and penetrance of MHS, a critical challenge for the field.
What We Already Know about This Topic
* Exome sequencing is likely to become more common in the movement toward personalized medicine
* A more thorough description of variants in genes associated with malignant hyperthermia may aid in interpreting the results of exome sequencing
What This Article Tells Us That Is New
* In 870 volunteers not ascertained for malignant hyperthermia susceptibility, numerous variants in RYR1 and CACNA1S genes were observed, some consistent and others inconsistent with presumed pathogenicity in current databases
MALIGNANT hyperthermia susceptibility (MHS) is a rare disorder of calcium dysregulation triggered by volatile anesthetics and the depolarizing muscle relaxant succinylcholine. It is an important cause of morbidity and mortality, and in its fulminant form manifests nearly always as metabolic and/or respiratory acidosis, rhabdomyolysis and hyperkalemia, as well some or all of the following symptoms: tachycardia, tachypnea, arrhythmias, skeletal muscle rigidity, and lethal hyperthermia. It is inherited in a predominately autosomal dominant pattern and associated with RYR1
mutations, with other mapped loci. Seventy to 86% of patients with MHS have RYR1
and 1% have CACNA1S
The prevalence and penetrance of MHS mutations are difficult to determine because the pharmacologic exposure rate is low and it is an inconsistently manifesting gene–environment interaction; that is, when a susceptible patient is exposed to a triggering agent, the probability of malignant hyperthermia (MH) is less than 100%.
Most MHS gene and variant studies have been performed on families with multiple generations affected with typical MHS. Studying these families made possible the discovery of the two implicated genes. However, these studies had ascertainment biases for those with severe reactions to the drugs. This has complicated efforts to establish the true prevalence and penetrance of MHS mutations.
In addition, assigning pathogenicity to RYR1
variants is challenging for several reasons. First is the issue of locus heterogeneity. With several mapped loci without identified genes, some RYR1
variants may have been erroneously determined to be pathogenic when there was a causative variant in another (untested) gene. In addition, RYR1
are large genes with 106 and 44 exons, respectively, making mutation screening challenging. Thus, some RYR1
variants previously determined to be pathogenic may be benign, as has been shown for other genes.7
New sequencing technologies, including exome sequencing (ES), have made sequencing of the human exome (exons of known genes) feasible. This provides the opportunity to detect mutations in MHS genes in a less biased manner. Using this approach, we can improve our understanding of the mutational spectra of the RYR1 and CACNA1S genes, and estimate their penetrance. Our objective was to identify mutations in RYR1 and CACNA1S in a population not ascertained for MHS, as a pilot for the use of exome data for predictive medicine.
Materials and Methods
To pilot the identification of MHS in an unselected population (mostly from the metropolitan areas of Washington D.C. and Baltimore in the United States), we evaluated ES data from the ClinSeq® study8
(n = 870)—a longitudinal cohort design to study the technical, medical, and genetic counseling issues associated with medical sequencing on large scale (i.e.
, exome or genome sequencing). The ClinSeq® study was reviewed and approved by the National Human Genome Research Institute’s Institutional Review Board (Bethesda, MD) and all subjects provided informed consent to publish results and deposit sequence data in databases. Participants were 45–65 yr of age at enrollment with a median age of 57 yr. These volunteers were unselected for MHS because they were ascertained for a spectrum of coronary artery disease, which is not associated with MHS. This sample of 870 participants was 89% Caucasian, 96.3% not of Hispanic or Latino background, and 49.7% female. Details of family history, race, ethnicity, current medical status, and clinical data were collected at enrollment, although a personal or family history of MHS was not specifically solicited. Race and ethnicity were determined by self-report on an intake questionnaire. First-degree relatives of another participant were excluded but one dyad of participants were first cousins and one dyad were first cousins once removed. During their initial visit, participants underwent an electrocardiogram, echocardiogram, and computed tomography scan for coronary calcium, clinical chemistries, and blood sample collection for genomic analysis. Sequence variants deemed clinically relevant were validated in a Clinical Laboratory Improvement Amendments–certified laboratory and the results returned to the participant.
The sequence data were generated at the National Institutes of Health’s Intramural Sequencing Center. The sequencing method used solution–hybridization exome capture, performed with the SureSelect All Exon System
(Version 1.0) from Agilent Technologies (Santa Clara, CA). The sequencing of 101 base-pair (paired-end reads) was performed with the GAIIx sequencer from Illumina, Inc. (San Diego, CA). One or two 101 base-pair, paired-end flow-cell lanes were sufficient to generate more than 85% coverage of the targeted exome with high-quality variant detection.9
Filters were applied with the VarSifter Next-Gen variation analysis software.§§10
DNA isolation, library preparation, capture, sequencing, and alignment and base calling were performed as described.11
variants were filtered for mutation type, frequency, and information in locus-specific mutation databases (LSDBs). The complementary DNA variants and their predicted protein changes are referred to by their protein designations in the text (see variant tables, Supplemental Digital Content 1, http://links.lww.com/ALN/A976
, and Supplemental Digital Content 2, http://links.lww.com/ALN/A977
, which are tables of the RYR1
variants identified in this study, respectively). RYR1
nucleotide numbering is based on transcript NM_000540.2, and CACNA1S
NM_000069.2, according to the Human Genome Variation Society nomenclature.‖ ‖
Variants with low genotype quality were designated class 0; the remainder were scored 1–5 using an adaptation of published criteria.12–17
Briefly, class 1 variants were definitely benign, class 2 probably benign, class 3 of uncertain pathogenicity, class 4 probably pathogenic, and class 5 definitely pathogenic. Further evaluation of the variants was performed using the Human Gene Mutation Database (HGMD)##18
and the LSDB, Leiden Open Variation Database (LOVD)***19
and for potentially pathogenic variants, review of the medical literature (table 1
). We elected not to use amino acid substitution mutation analysis tools because their predictive power is variable.
Medical histories of the probands and their pedigrees were reviewed for diagnoses or symptoms of MHS and related disorders. We learned retrospectively that one participant self-referred to the study because of a clinical diagnosis of MHS (subsequently found to have RYR1 p.Asp3986Glu). Clinically relevant results were returned to participants for management. For the family with a history of MH, we used standard linkage methods, typing short tandem repeat polymorphism markers and polymerase chain reaction amplification and Sanger sequencing of exons not covered by exome data.
The sequencing coverage (defined as the number of coding base-pairs with quality calls/total number of targeted base-pairs) of the coding exons was 83% (RYR1
) and 93% (CACNA1S
) (fig. 1
), and there exists an inherent risk of false negatives. Sequence coverage is dependent on many factors including DNA quality, capture efficiency, percent GC (guanine-cytosine) content, and repeat elements. Our average depth of coverage in the target region for each sample was 89x.
variant was a false positive, recognized by its marginal most probable genotype score and confirmed by manual review of sequence reads. We identified 123 total variants, 70 in RYR1
and 53 in CACNA1S
, among 870 exomes. These variants were identified in 1–419 participants, each. Seventeen of the 122 variants (7 RYR1
and 11 CACNA1S
) were excluded because they were too common (fig. 2
, and see the RYR1
variant tables Supplemental Digital Content 1, http://links.lww.com/ALN/A976
, and Supplemental Digital Content 2, http://links.lww.com/ALN/A977
). The National Heart, Lung, and Blood Institute, Exome Variant Server†††
frequency threshold was set to 0.5% as this was approximately 10-fold higher than the higher end of the MHS prevalence estimate,1
and the ClinSeq® frequency was set to 1% because it includes approximately 1/10 as many exomes as the Exome Variant Server and therefore chance variation could inadvertently exclude a variant. Our focus was on the identification of highly penetrant alleles that cause autosomal dominant MHS, though we did detect some recessive myopathy alleles.
The remaining 104 variants (63 in RYR1
and 41 in CACNA1S
) were considered rare variants. Seventeen of the 63 RYR1
rare variants were listed in the HGMD as “disease-causing” for either MHS, central core disease, multiminicore disease, atypical periodic paralysis, or congenital myopathy. Three of the 63 RYR1
variants were not present in HGMD but were listed in the LSDB as pathogenic. One of the 41 CACNA1S variants (p.Thr1354Ser) was listed in HGMD as pathogenic for MHS, and one (p.Arg498His) was listed in the LSDB as pathogenic but without any supporting evidence. Of the 20 RYR1
variants (present in HGMD or LSDBs, and with an allele frequency <1%), only four met our criteria (table 1
) for class 5 pathogenicity; the remaining 16 were scored as a 3 (variants of unknown significance) or class 2 (likely not pathogenic).
Four class 5 RYR1
variants were identified in 870 exomes. The p.Arg614Cys variant was found in one participant and listed in HGMD as pathogenic based on three publications20–22
and reported 37 times in LOVD. All the submitting authors of these entries had concluded that it was pathogenic. This p.Arg614Cys variant is one of the 31 RYR1 mutations on the European Malignant Hyperthermia Group‡‡‡
list of pathogenic mutations and is also included in the 2002 North American MH consensus list of 17 causative mutations.23
We designated this mutation as class 5, pathogenic. It is interesting to note that the 62-yr-old female participant with this variant had no family or personal history of MHS, despite having surgery with general anesthesia thrice.
The second class 5 RYR1 pathogenic variant, p.Arg2241X, was detected in two participants. It was described as pathogenic in HGMD, based on a single patient with congenital myopathy, episodes of generalized, atypical normokalemic paralysis, and multiminicore disease with external ophthalmoplegia and episodes of atypical periodic paralysis.24
The molecular data in this published report were complex. The patient had, in addition to p.Arg2241X, p.Asp708Asn in cis and p.Arg2939Lys in trans
to p.Arg2241X with apparent nonsense-mediated messenger RNA decay of the p.Arg2241X-bearing allele. In another study of 37 patients with dominant or recessive RYR1
-related myopathies, the p.Arg2241X variant was described in three patients with recessive myopathies and ophthalmoparesis.25
In two siblings, 7 and 5 yr old, the p.Arg2241X variant cooccurred with the previously described putatively pathogenic variant p.Arg109Trp,26
and in a third patient the p.Arg2241X variant cooccurred with two missense variants, the putatively pathogenic p.Arg2939Lys27
and p.Asp708Asn (these three variants were likely from the same patient reported in two case series by this same group).24
The RYR1 variant p.Arg2241X was also categorized as a pathogenic recessive mutation in a patient with a congenital myopathy and muscle biopsy finding of an RYR1
-related myopathy from a study of 71 families with RYR1
The patient had two additional recessive pathogenic variants, p.Asp708Asn and p.Met485Val, and a synonymous variant of unknown significance c.11547G>A (p(=)). The p.Arg2241X variant was not detected in the Exome Variant Server. We categorized p.Arg2241X as class 5 because it was described in affected patients and of the category of variants (nonsense) strongly predictive of an autosomal recessive RYR1
The third class 5 RYR1
variant, c.5183C>T; p.Ser1728Phe, was listed in HGMD with references to two studies as pathogenic.5
We found this variant in a 47-yr-old (Irish/British ancestry) female (1/1,740 alleles) without a personal or family history of MHS. The p.Ser1728Phe variant was reported in three independent families from an analysis of the U.K. MH patients.5
In a subsequent genotype–phenotype correlation study, the p.Ser1728Phe variant was found in seven individuals and two families—six with a weaker in vitro
contraction test phenotype compared with the known pathogenic p.Gly2434Arg mutation, suggesting a lesser effect on channel function as compared with their control.22
Because the rare p.Ser1728Phe variant (1/10,757 alleles in the Exome Variant Server) was reported multiple times as pathogenic, with no evidence against, it was scored as a class 5, pathogenic variant.
The fourth class 5 RYR1
variant, c.11958C>G; p.Asp3986Glu, was listed in HGMD with references to the same two U.K. studies cited above.5
The variant was seen in five MH patients with MH disease status and associated with more severe static caffeine contractures and higher creatine kinase levels than the p.Gly2434Arg control or other variants. It was also identified in one 45-yr-old (Irish/German ancestry) male, ClinSeq® volunteer (1/1,740 alleles) with a history of MH. The volunteer had a history of multiple fulminant MH events—symptoms of myopathy, myotonia (dysphagia), proximal muscle weakness, and a positive in vitro
contracture test and a serum creatine kinase value of 1,271 U/l and lactate dehydrogenase level of 238 U/l (see participant description table, Supplemental Digital Content 3, http://links.lww.com/ALN/A978
, which is a table containing the characteristics of the ClinSeq® volunteers with RYR1
variants). In addition, he had a family history of myotonia and positive in vitro
contracture test in three siblings. This rare RYR1 variant, which resides in MHS mutational hotspot region III, was not found in more than 6,500 human exomes in Exome Variant Server. Since it has been reported multiple times as pathogenic with no evidence against pathogenicity, we concluded this was a class 5, pathogenic mutation.
Of the 20 rare RYR1
variants (17 in HGMD and the LSDBs, 3 in LSDBs only) that were identified in ClinSeq®—10 were assigned to class 3, and 6 to class 2, based on the criteria in the pathogenicity table. The reasoning for these assignments is described in the Supplemental Digital Content 4, http://links.lww.com/ALN/A979
, Supplemental Methods, which describes the variants—of less than class 5 pathogenicity—identified in ClinSeq® and in databases. The family, personal, medical, and surgical histories of all participants with RYR1
variants were reviewed; all but two were negative for MHS (see participant description tables, Supplemental Digital Content 3, http://links.lww.com/ALN/A978
, and Supplemental Digital Content 5, http://links.lww.com/ALN/A980
, containing the characteristics of the ClinSeq® volunteers with RYR1
One participant was found to have a novel RYR1 missense variant p.Arg3498Gly and a three-generation family history of MHS with an in vitro
contracture test diagnostic for MHS.29
To assess the potential pathogenicity of this variant, we performed a segregation analysis of the variant in the family. The variant did not segregate with the MHS phenotype (see Supplemental Digital Content 6, http://links.lww.com/ALN/A981
, a pedigree of the MH family). We ruled out an error in phenotyping, after acquiring muscle biopsy and caffeine halothane contracture test results for seven of the family members from The North American Malignant Hyperthermia Registry.§§§
We next performed a candidate linkage analysis of the RYR1
locus. Genotyping and manual haplotyping showed that an RYR1
haplotype cosegregated with the phenotype, but this haplotype was in trans
to p.Arg3498Gly. We concluded that p.Arg3498Gly was not pathogenic and hypothesized that this family most likely had MHS attributable to an undetected RYR1
variant in trans to p.Arg3498Gly in the proband. We next evaluated the exon coverage of RYR1
in this proband and found that he had 91.9% sequence coverage. We performed a Sanger sequencing of exons with poor exome sequence read-depth but found no mutations. We concluded that the ES of RYR1
generated both a false-negative and a false-positive result in that the p.Arg3498Gly is not pathogenic and the participant likely has a mutation in RYR1
not captured by ES or Sanger sequencing.
One of the 41 CACNA1S rare variants, p.Arg498His, identified in one exome, was listed in LOVD as pathogenic (it was not listed in HGMD). However, the pathogenicity of this entry was not supported by the primary literature, nor did LOVD provide details of the CACNA1S-associated phenotype. We contacted the LOVD curators and learned that the variant had been recategorized as “unknown pathogenicity,” although the database itself had not been updated. We therefore categorized it as a variant of uncertain significance (score 3).
The CACNA1S variant p.Thr1354Ser was identified in 9 of 870 ClinSeq® exomes (minor allele frequency 0.7%) and in the Exome Variant Server with an allele count of 48 of 12,958 (minor allele frequency 0.4%). HGMD listed this variant as pathogenic, citing a publication showing segregation of p.Thr1354Ser in one family, its absence in 282 controls, and functional data demonstrating abnormal Ca++
However, we concluded that this was more likely a benign variant in linkage disequilibrium with the (undetected) true pathogenic variant in the family described by Pirone et al.30
Of the remaining 39 CACNA1S
rare variants, none were present in either HGMD or the LSDBs. These variants were also assigned to class 3. None of these patients had a personal or family history of MHS (see Supplemental Digital Content 5, http://links.lww.com/ALN/A980
, with the characteristics of the ClinSeq® volunteers with CACNA1S
Four examples of both the power and the limitations of ES for studying MHS were identified in this study. First, we detected a causative (class 5) RYR1 mutation, p.Arg614Cys, in a proband who had no clinical/phenotypic evidence of MHS and a negative family history (see participant description table, Supplemental Digital Content 3, http://links.lww.com/ALN/A978
). The p.Arg614Cys variant was included in both the North American MHS and the European Malignant Hyperthermia Group causative mutation lists. We conclude that this represents a presymptomatic diagnosis of MHS in this participant, which is an example of the predictive, personalized genomic medicine in practice. We confirmed this variant in a clinical testing lab, returned it to the participant with medical and genetic counseling, and referred her for consideration for caffeine halothane contracture test testing and enrollment in the Malignant Hyperthermia Association of the U.S. registry. Until such testing is performed on the patient or she has a reaction to a triggering agent, we cannot claim to have proven she has MHS. However, because this variant is listed in both the North American MHS and the European Malignant Hyperthermia Group causative mutation lists, we believe that it is extremely unlikely that this variant is benign solely because it was ascertained in context of this study design. Second, the p.Thr1354Ser CACNA1S variant, previously assumed to be pathogenic, was deemed likely to be class 3, that is, of uncertain pathogenicity. The frequency of this single variant was approximately 20 times higher than the frequency of MHS attributed to all loci and all mutations (0.74–1% p.Thr1354Ser heterozygotes). Although there are good functional data implicating this variant30
in MHS, we believe that the population genetic data mandate that it should be scored class 3, of unknown pathogenicity. Our findings, supported by the Exome Variant Server CACNA1S
allele frequencies, suggest that other previously implicated MHS variants may be benign. Caution is warranted regarding variants claimed to be causative for MHS, especially when used for predictive individualized medicine. Third, we found a novel RYR1 p.Arg3498Gly variant that was not
pathogenic in an individual positive for MH by the caffeine halothane contracture test and a family history of MHS. The variant was rare but did not segregate with the phenotype, and this family most likely had MHS attributable to an undetected RYR1
variant, or, less likely, a variant at another locus. We suggest that other previously reported rare RYR1
variants without robust genetic data may have been misclassified as pathogenic. Fourth, we identified the class 5 variant, p.Arg2241X, which has been associated with phenotypes inherited in a recessive pattern, but recent publications have questioned the pathogenicity of this variant.15
The risk of MHS in most recessive myopathies is uncertain, and has only been proven for central core disease.31
This example shows that even when one can identify pathogenic variants, it can be challenging to associate them unequivocally with specific phenotypes.
Using ES, we identified 123 distinct variants (70 RYR1
and 53 CACNA1S
) among 870 participants (figs. 3
). Our analyses yielded a spectrum of pathogenicity scores from benign to pathogenic (figs. 5
). All but two of the RYR1
variants classified as “disease causing mutations” in HGMD were reclassified by us as benign, probably benign, or variant of unknown significance, scores 1–3. We reclassified these variants based on the criteria in table 1
, under the assumption that a variant was benign, unless a critical review of the data supported a higher pathogenicity category. It is critical to recognize that our assessment of “benign” or “probably benign” is limited to the specific context of using such a variant for individualized predictive medicine and that it is certainly not our intention for it to be interpreted to mean that the variant has no role in the pathogenicity of MHS, myopathy, or other phenotypes. In addition, more than half of the RYR1
variants (43 of 69, 62%) we identified were not listed by HGMD or the LSDB databases, or in biomedical literature citations. Because we screened a cohort unselected for MHS, we predicted that most of the novel variants would be benign. More than half (40 of 69) of the RYR1
variants were rare and not found in the Exome Variant Server. A fifth (10 of 51) of the CACNA1S
variants were common polymorphisms, which we assigned to class 1 (benign), with the remaining assigned to class 3 (unknown; fig. 6
). Four individuals (three males, one female) had more than one RYR1
variant and two of the four participants with two RYR1
variants had benign CACNA1S
variants as well (see Supplemental Digital Content 3, http://links.lww.com/ALN/A978
, and Supplemental Digital Content 5, http://links.lww.com/ALN/A980
, containing the characteristics of the ClinSeq® volunteers with RYR1
The purpose of this study was to identify high-penetrance variants associated with MHS. As noted above, that we conclude a variant is class 1–3 does not automatically mean that the variant has no physiological effects. Moreover, the data did not allow us to evaluate whether interactions could have occurred among variants in a given individual,5
although this should be specifically addressed in future studies. We deliberately set our threshold for pathogenicity high to avoid the error of wrongly diagnosing an individual as susceptible in an ascertainment mode where the previous probability that they are affected was low. The risk of false negatives in ES will diminish as future ES and follow-up studies generate additional data.
The filtering process for analysis of MHS variants from ES requires a manual method of evaluating variants to extract meaningful information. We used allele frequency, genotype–phenotype databases, and the primary literature to identify pathogenic variants. Unfortunately, there is at present no single information source that allows one to reliably ascertain whether a variant is benign or pathogenic. Many sequence databases (e.g., the Exome Variant Server and The Single Nucleotide Polymorphism Database) include pathogenic, potentially pathogenic and nonpathogenic variants and do not include phenotype data. Furthermore, there is often no indication as to whether some individuals harbor multiple variants within a single gene, which limited our ability to evaluate these data. Our evaluation of 870 exomes using HGMD and LSDBs indicated likely significant levels of misclassification and variability in the pathogenicity determination not only in HGMD and the LSDBs, which is primarily attributable to the source literature.
Exome sequencing has some limitations: the method can miss pathogenic variants such as structural variation, or copy-number variants, in the genome—larger insertions and deletions, duplications, and inversions. Although technology has improved target coverage over the years, it will most likely never reach 100%. In view of the distribution of variants and the complexity of the genome, ES remains an efficient way to identify most mutations altering protein sequence in any single DNA sample. However, to our knowledge, to date the only genomic variants associated with MH are missense variants in coding exons, so most of these limitations do not pertain, given our current knowledge of the disorder.
The published prevalence of MHS mutations varies widely from 1 in 2,0001
to 1 in 10,0004
but the penetrance has been difficult to determine. Our study of 870 exomes, although it represents a prodigious amount of data, is still too small to estimate the prevalence of MHS. The ES of patients not ascertained for a personal or family history of MHS allows, in principle, an unbiased approach to genotype–phenotype correlation that has not been feasible with previous technologies. We conclude that some RYR1
variants may have been misclassified as pathogenic without adequate genetic (e.g.
, cosegregation) or functional data. It is important to stress that in addition to robust genetic analysis, there is a critical need for a robust and noninvasive functional test for MHS, which together with genetic data could allow accurate determination of the prevalence and penetrance of this trait. Presently, ES cannot replace clinical investigations, but rather assists clinicians in determining which patients should undergo further genetic and/or functional analyses. This approach to variant identification in MHS should be extended to other cohorts undergoing ES, and may be useful as a first screening approach, before more invasive and time-consuming investigations. Analysis of thousands of exomes has the potential to provide the MHS field with an exhaustive catalog of variants to determine the true prevalence, penetrance, and expressivity of this life-threatening disorder. Although the assessment of the pathogenicity of both known and novel variants remains challenging, we demonstrate that causative mutations can be identified from ES data. These data suggest that clinically relevant mutations can be identified as incidental findings in exomes sequenced for clinical care and clinical research. This should inform the debate on the return of such secondary results to research participants. Furthermore, the application of ES technology to large and diverse cohorts has the potential to accelerate the pace of MHS gene mutation discovery. We speculate that the results of these studies will allow the development of clinical genomic screening for MHS, which should reduce the incidence of life-threatening events and increase life expectancy for those individuals who harbor pathogenic variants in these genes.
The authors thank the staff at the National Institutes of Health (NIH) Intramural Sequencing Center, NIH Clinical Center, and the ClinSeq® study participants. Caitlin Joy Krause, B.S., Iowa City, Iowa, provided technical support and Flavia M. Facio, M.S., C.G.C., Bethesda, Maryland, provided clinical support. Sheila Muldoon, M.D., Professor, Department of Anesthesiology of the Uniformed Services University of the Health Sciences, provided advice and support.
§§ The VarSifter program website. A graphical software program designed to view massively parallel sequencing variation output. Available at: http://research.nhgri.nih.gov/software/VarSifter/index.shtml
. Accessed June 30, 2013. Cited Here...
‖‖ The Human Genome Variation Society website. Nomenclature for the description of sequence variations. Available at: www.hgvs.org/mutnomen/
. Accessed May 20, 2013. Cited Here...
## The Human Gene Mutation Database (HGMD), Professional version 2012.2 from BIOBASE. A database of germline mutations in genes associated with human inherited disease. Available at: www.hgmd.org
. Accessed May 20, 2013. Cited Here...
*** Leiden Open Variation Database (LOVD), v.3.0. Available at: www.lovd.nl/3.0/home
. Accessed May 20, 2013. Cited Here...
††† The National Heart, Lung, and Blood Institute’s, Exome Sequencing Project, data browser. Available at: http://evs.gs.washington.edu/EVS/
. Accessed May 20, 2013. Cited Here...
‡‡‡ The European Malignant Hyperthermia Group website. Available at: www.emhg.org/home
. Accessed May 20, 2013. Cited Here...
§§§ The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Available at: www.mhaus.org/registry/#.USKCe-2TxsQ
. Accessed May 20, 2013. Cited Here...
1. Ibarra M CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I. Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. ANESTHESIOLOGY. 2006;104:1146–54
2. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. ANESTHESIOLOGY. 2005;102:515–21
3. Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum Mutat. 2006;27:830
4. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J. Presence of two different genetic traits in malignant hyperthermia families: Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. ANESTHESIOLOGY. 2002;97:1067–74
5. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006;27:977–89
6. Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet. 2001;59:178–84
7. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3:65ra4
8. Biesecker LG, Mullikin JC, Facio FM, Turner C, Cherukuri PF, Blakesley RW, Bouffard GG, Chines PS, Cruz P, Hansen NF, Teer JK, Maskeri B, Young AC, Manolio TA, Wilson AF, Finkel T, Hwang P, Arai A, Remaley AT, Sachdev V, Shamburek R, Cannon RO, Green EDNISC Comparative Sequencing Program. . The ClinSeq Project: Piloting large-scale genome sequencing for research in genomic medicine. Genome Res. 2009;19:1665–74
9. Teer JK, Bonnycastle LL, Chines PS, Hansen NF, Aoyama N, Swift AJ, Abaan HO, Albert TJ, Margulies EH, Green ED, Collins FS, Mullikin JC, Biesecker LGNISC Comparative Sequencing Program. . Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. Genome Res. 2010;20:1420–31
10. Teer JK, Green ED, Mullikin JC, Biesecker LG. VarSifter: Visualizing and analyzing exome-scale sequence variation data on a desktop computer. Bioinformatics. 2012;28:599–600
11. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG. Secondary variants in individuals undergoing exome sequencing: Screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet. 2012;91:97–108
12. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SVIARC Unclassified Genetic Variants Working Group. . Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91
13. Akbari MR, Zhang S, Fan I, Royer R, Li S, Risch H, McLaughlin J, Rosen B, Sun P, Narod SA. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. J Med Genet. 2011;48:783–6
14. Bergman JE, Janssen N, van der Sloot AM, de Walle HE, Schoots J, Rendtorff ND, Tranebjaerg L, Hoefsloot LH, van Ravenswaaij-Arts CM, Hofstra RM. A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Hum Mutat. 2012;33:1251–60
15. Greenblatt MS, Brody LC, Foulkes WD, Genuardi M, Hofstra RM, Olivier M, Plon SE, Sijmons RH, Sinilnikova O, Spurdle ABIARC Unclassified Genetic Variants Working Group. . Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat. 2008;29:1273–81
16. Jordan DM, Kiezun A, Baxter SM, Agarwala V, Green RC, Murray MF, Pugh T, Lebo MS, Rehm HL, Funke BH, Sunyaev SR. Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet. 2011;88:183–92
17. Thompson BA, Greenblatt MS, Vallee MP, Herkert JC, Tessereau C, Young EL, Adzhubey IA, Li B, Bell R, Feng B, Mooney SD, Radivojac P, Sunyaev SR, Frebourg T, Hofstra RM, Sijmons RH, Boucher K, Thomas A, Goldgar DE, Spurdle AB, Tavtigian SV. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat. 2013;34:255–65
18. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat. 2003;21:577–81
19. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v.2.0: The next generation in gene variant databases. Hum Mutat. 2011;32:557–63
20. Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab. 2011;104:167–73
21. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991;11:751–5
22. Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth. 2009;103:538–48
23. Sei Y, Sambuughin N, Muldoon S. Malignant hyperthermia genetic testing in North America Working Group Meeting. Bethesda, Maryland. September 4-5, 2002. ANESTHESIOLOGY. 2004;100:464–5
24. Zhou H, Lillis S, Loy RE, Ghassemi F, Rose MR, Norwood F, Mills K, Al-Sarraj S, Lane RJ, Feng L, Matthews E, Sewry CA, Abbs S, Buk S, Hanna M, Treves S, Dirksen RT, Meissner G, Muntoni F, Jungbluth H. Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord. 2010;20:166–73
25. Klein A, Jungbluth H, Clement E, Lillis S, Abbs S, Munot P, Pane M, Wraige E, Schara U, Straub V, Mercuri E, Muntoni F. Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations. Arch Neurol. 2011;68:1171–9
26. Zhou H, Yamaguchi N, Xu L, Wang Y, Sewry C, Jungbluth H, Zorzato F, Bertini E, Muntoni F, Meissner G, Treves S. Characterization of recessive RYR1 mutations in core myopathies. Hum Mol Genet. 2006;15:2791–803
27. Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H, Rose MR, Brockington M, Kinali M, Manzur A, Robb S, Appleton R, Messina S, D’Amico A, Quinlivan R, Swash M, Müller CR, Brown S, Treves S, Muntoni F. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain. 2007;130(Pt 8):2024–36
28. Klein A, Lillis S, Munteanu I, Scoto M, Zhou H, Quinlivan R, Straub V, Manzur AY, Roper H, Jeannet PY, Rakowicz W, Jones DH, Jensen UB, Wraige E, Trump N, Schara U, Lochmuller H, Sarkozy A, Kingston H, Norwood F, Damian M, Kirschner J, Longman C, Roberts M, Auer-Grumbach M, Hughes I, Bushby K, Sewry C, Robb S, Abbs S, Jungbluth H, Muntoni F. Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat. 2012;33:981–8
29. Rosenberg H, Sambuughin N, Dirksen RPagon RA, Bird TD, Dolan CR, Stephens K, Seattle WA. Malignant hyperthermia susceptibility GeneReviews. 1993 Seattle University of Washington
30. Pirone A, Schredelseker J, Tuluc P, Gravino E, Fortunato G, Flucher BE, Carsana A, Salvatore F, Grabner M. Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit. Am J Physiol Cell Physiol. 2010;299:C1345–54
31. Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM. Core myopathies and risk of malignant hyperthermia. Anesth Analg. 2009;109:1167–73
32. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21
The NIH Intramural S...Image Tools
Supplemental Digital Content
© 2013 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.